BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

980 related articles for article (PubMed ID: 12527708)

  • 1. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
    Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
    Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
    Kiss A; Wang NJ; Xie JP; Thorgeirsson SS
    Clin Cancer Res; 1997 Jul; 3(7):1059-66. PubMed ID: 9815784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
    Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
    Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
    Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
    Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does.
    D'Errico A; Fiorentino M; Ponzetto A; Daikuhara Y; Tsubouchi H; Brechot C; Scoazec JY; Grigioni WF
    Hepatology; 1996 Jul; 24(1):60-4. PubMed ID: 8707284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
    Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
    Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
    Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
    Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers.
    Bedossa P; Peltier E; Terris B; Franco D; Poynard T
    Hepatology; 1995 Mar; 21(3):760-6. PubMed ID: 7875675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
    Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
    Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma.
    Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
    Hepatology; 1997 Mar; 25(3):619-23. PubMed ID: 9049208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor.
    Neaud V; Faouzi S; Guirouilh J; Le Bail B; Balabaud C; Bioulac-Sage P; Rosenbaum J
    Hepatology; 1997 Dec; 26(6):1458-66. PubMed ID: 9397985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma.
    Varnholt H; Asayama Y; Aishima S; Taguchi K; Sugimachi K; Tsuneyoshi M
    Oncol Rep; 2002; 9(1):35-41. PubMed ID: 11748452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
    Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
    Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
    Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.
    Buckley AF; Burgart LJ; Kakar S
    Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.
    Osada S; Kanematsu M; Imai H; Goshima S
    Hepatogastroenterology; 2008; 55(82-83):544-9. PubMed ID: 18613405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma.
    Nagata K; Hirono S; Ido A; Kataoka H; Moriuchi A; Shimomura T; Hori T; Hayashi K; Koono M; Kitamura N; Tsubouchi H
    Biochem Biophys Res Commun; 2001 Nov; 289(1):205-11. PubMed ID: 11708800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.